Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue

AIDS

Volumn 10, Issue 1, 1996, Pages 47-53

  McGavin, Catherine H ^a   Land, Sally A ^a   Sebire, Kim L ^a   Hooker, David J ^b   Gurusinghe, Asitha D ^b   Birch, Chris J ^a  

^a FAIRFIELD HOSPITAL   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

Autopsy tissues; HIV 1; Lymph node; Syncytium inducing phenotype; Zidovudine susceptibility

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ARTICLE; AUTOPSY; BRAIN; CEREBROSPINAL FLUID; CODON; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPINAL CORD; SPLEEN; SYNCYTIUM; T LYMPHOCYTE; VIRUS ISOLATION;

EID: 0030026351     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199601000-00007     Document Type: Article

References (28)

1. Land SA, Treloar G, McPhee DA, et al.: Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 1990, 161:326-369.
2. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1731-1734.
3. Richman DD, Grimes JM, Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990, 3:743-746.
4. Rooke R, Tremblay M, Soudeyns H, et al.: Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989, 3:411-415.
5. Boucher CAB, Tersmette M, Lange JMA, et al.: Zidovudine sensitivity of human immunodeficiency virus from high-risk, symptom free individuals during therapy. Lancet 1990, 336:585-589.
6. Di Stefano M, Norkrans G, Chiodi F, Hagberg L, Nielsen C, Svennerholm B: Zidovudine-resistant variants of HIV-1 in the brain. Lancet 1993, 342:865-866.
7. Land SA, McGavin KH, Birch CJ, Lucas R: Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet 1991, 338:830-831.
8. Albert J, Wahlberg J, Lundeberg J, et al.: Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol 1992, 66:5627-5630.
9. Boucher CAB, van Leevwen R, Kellam P, et al.: Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993, 37:1525-1530.
10. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993, 167:526-532.
11. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
12. Koot M, Keet IPM, Vos AHV, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
13. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
14. Embretson J, Zupancic M, Ribas JL, et al.: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
15. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011-1018.
16. Neate EV, Pringle RC, Jowett JBM, Healey DS, Gust ID: Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Aust NZ J Med 1987, 17:461-466.
17. Land SA, McGavin CH, Lucas R, Birch CJ: Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J Infect Dis 1992, 166:1139-1142.
18. Gregerson JP, Wege H, Preiss L, Jentsch KD: Detection of human immunodeficiency virus and other retroviruses in cell culture supernatants by a reverse transcriptase microassay. J Virol Methods 1988, 189:161-168.
19. Gurusinghe AD, Land SA, Birch CJ, et al.: Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol 1995, 46:238-243.
20. Myers G, Korber B, Wain-Hobson S, Smith RF, Pavlakis GN (Eds): Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos: Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory; 1993.
21. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain terminator inhibitors. Proc Natl Acad Sci USA 1977, 74:5463-5467.
22. Nyberg M, Suni J, Haltia M: Isolation of human immunodeficiency virus (HIV) at autopsy one to six days post-mortem. Am J Clin Pathol 1990, 94:422-425.
23. Douceron H, Deforges L, Gheradi R, Sobel A, Chariot P: Long-lasting post-mortem viability of human immunodeficiency virus: a potential risk in forensic medicine practice. Forensic Sci Int 1993, 60:61-66.
24. Crumpacker C, Welles S, Yen-Liebeman, et al.: Correlation of plasma HIV-1 RNA level and development of resistance mutations to AZT and ddl with disease progression in patients with advanced HIV-1 disease and little or no AZT therapy. Presented at the HIV Drug Resistance Fourth International Workshop. Sardinia, July 1995.
25. St Clair MH, Martin JL, Tudor WG, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
26. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human deficiency type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transsciptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
27. Wei X, Ghosh SK, Taylor ME et al.: Viral dynamics in human immunodeficiency virus type T infection. Nature 1995, 373:117-122.
28. Ho D, Neumann A, Perelson A, et al.: Rapid turnover of plasma virions and CD4 lymphocytesin HIV-1 infection. Nature 1995, 373:123-126.